Loading…
Personalis, Inc. is projected to rise to $10.55 by 2027, a +11% move from its current price of $9.49. PSNL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $9.07 | $9.49 | $9.93 | +0.02% |
| May 30 | $8.90 | $9.49 | $10.13 | +0.04% |
| May 31 | $8.77 | $9.50 | $10.28 | +0.06% |
| Jun 1 | $8.67 | $9.50 | $10.40 | +0.08% |
| Jun 2 | $8.58 | $9.50 | $10.52 | +0.10% |
| Jun 3 | $8.50 | $9.50 | $10.62 | +0.12% |
| Jun 4 | $8.42 | $9.50 | $10.72 | +0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.42 | $9.50 | $10.72 | +0.14% |
| Week 2 | $8.02 | $9.52 | $11.29 | +0.27% |
| Week 3 | $7.73 | $9.53 | $11.74 | +0.41% |
| Week 4 | $7.50 | $9.54 | $12.15 | +0.55% |
| Week 5 | $7.30 | $9.56 | $12.52 | +0.69% |
| Week 6 | $7.12 | $9.57 | $12.86 | +0.83% |
| Week 7 | $6.96 | $9.58 | $13.19 | +0.97% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.
In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients.
The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
PSNL, the stock of Personalis, Inc., is currently priced at $9.49 and has a market capitalization of $993.8M. It ranks 2509 by market cap among listed equities. The current price sits in a landscape of a volatile sector with a 30-day range noted as $7.03 to $12.82 and a high observed sentiment indicated by a bullish reading.
The long-range forecast shows upside potential, with the average price rising over time from $9.49 in 2026 to $151.56 in 2050 and a max reach of $348.59 by 2050, yielding substantial upside potential in the out years. The forecast includes year-by-year expectations for min, avg, max prices and ROI, underscoring a bullish longer-term trajectory while acknowledging near-term uncertainty.
A major floor 62.5% below — a decisive break under it would weaken the trend.
The nearest floor, 46.9% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 31.3% above — clearing it would confirm fresh momentum.
Key PSNL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PSNL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.62 | Buy | $8.62 | Buy |
| MA 10 | $7.63 | Buy | $7.90 | Buy |
| MA 20 | $6.70 | Buy | $7.23 | Buy |
| MA 50 | $6.63 | Buy | $7.00 | Buy |
| MA 100 | $7.69 | Buy | $7.28 | Buy |
| MA 200 | $7.60 | Buy | $7.18 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 77.69 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 186.48 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.38 | Buy |
| ROC (12) | 58.70 | Buy |
| Bollinger %B (20,2) | 1.07 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.55 | Buy |
| Awesome (5,34) | 2.11 | Buy |
| Ultimate (7,14,28) | 91.29 | Sell |
| Momentum (10) | 3.45 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 9.40 | Buy |
| ADX (14) | 24.57 | Buy |
| ATR (14) | 0.34 | Info |
The near-term technical picture is bullish, with sentiment labeled as BULLISH and RSI14 at 80. The stock is trading above the 50-day simple moving average of $6.63 and the 200-day simple moving average of $7.60. Key support is identified at $5.04 and resistance at $9.49.
Over the last 30 days the price has traded within a range of $7.03 to $12.82, illustrating a broad range of near-term movement.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.04 | $9.49 | $14.74 | 0% | Neutral | |
| $7.83 | $10.55 | $15.34 | +11% | Neutral | |
| $9.57 | $13.56 | $20.80 | +43% | Bullish | |
| $12.01 | $17.73 | $28.38 | +87% | Bullish | |
| $13.97 | $21.42 | $35.52 | +126% | Bullish | |
| $17.14 | $27.24 | $46.57 | +187% | Bullish | |
| $18.06 | $29.66 | $52.11 | +213% | Bullish | |
| $17.86 | $30.29 | $54.54 | +219% | Bullish | |
| $18.25 | $31.92 | $58.78 | +236% | Bullish | |
| $18.14 | $32.69 | $61.46 | +244% | Bullish | |
| $29.47 | $61.20 | $125.35 | +545% | Bullish | |
| $68.20 | $151.56 | $348.59 | +15.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.04 | $9.49 | $11.24 | +0.00% |
| June 2026 | $7.84 | $9.34 | $11.50 | -1.56% |
| July 2026 | $7.99 | $9.66 | $12.15 | +3.42% |
| August 2026 | $8.55 | $10.45 | $13.36 | +8.15% |
| September 2026 | $8.56 | $10.56 | $13.69 | +1.08% |
| October 2026 | $8.28 | $10.31 | $13.53 | -2.35% |
| November 2026 | $8.51 | $10.67 | $14.15 | +3.47% |
| December 2026 | $8.71 | $11.00 | $14.74 | +3.13% |
Click any year to see its month-by-month PSNL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, PSNL is projected to trade between $5.04 and $14.74, averaging $9.49 — a potential gain of 0% from today's $9.49. Price action looks broadly range-bound.
Personalis, Inc.'s 2027 outlook centres on $10.55, within a $7.83 to $15.34 range. That is up +11% on the projected 2026 average. That marks a +11% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, PSNL could reach as high as $20.80, with a base case around $13.56 and support toward $9.57 — roughly +43% from $9.49. Momentum favours further upside here.
Expect PSNL to range from $12.01 to $28.38 through 2029. The $17.73 average target implies a +87% move from current prices. That is up +31% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The PSNL price prediction for 2030 points to an average of $21.42 (low $13.97, high $35.52) — a potential gain of +126% on today's $9.49. Momentum favours further upside here.
In 2031, PSNL is projected to trade between $17.14 and $46.57, averaging $27.24 — a potential gain of +187% from today's $9.49. That is up +27% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Personalis, Inc.'s 2032 outlook centres on $29.66, within a $18.06 to $52.11 range. That is up +9% on the projected 2031 average. That marks a +213% change versus current levels. Momentum favours further upside here.
By 2033, PSNL could reach as high as $54.54, with a base case around $30.29 and support toward $17.86 — roughly +219% from $9.49. Buyers look set to stay in control over this stretch.
Expect PSNL to range from $18.25 to $58.78 through 2034. The $31.92 average target implies a +236% move from current prices. That is up +5% on the projected 2033 average. Momentum favours further upside here.
The PSNL price prediction for 2035 points to an average of $32.69 (low $18.14, high $61.46) — a potential gain of +244% on today's $9.49. Buyers look set to stay in control over this stretch.
In 2040, PSNL is projected to trade between $29.47 and $125.35, averaging $61.20 — a potential gain of +545% from today's $9.49. That is up +87% on the projected 2035 average. Momentum favours further upside here.
Personalis, Inc.'s 2050 outlook centres on $151.56, within a $68.20 to $348.59 range. That is up +148% on the projected 2040 average. That marks a +15.0x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in PSNL today (≈ 105.374078 PSNL) could be worth
$15,970.62
+$14,970.62 (+1497%) by 2050 · US Dollar
Based on the average projected PSNL price of $151.56 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PSNLwould be worth at today's price.
$1,000 invested in PSNL on May 27, 2025 (≈ 213.219614 PSNL) would be worth
$2,023.45
+$1,023.45 (+102.3%) today · 2.02× · US Dollar
Based on a PSNL entry price of $4.69 vs. today's $9.49.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.95 | $1,193.71 | +19.4% |
| 1 month ago | $5.96 | $1,592.28 | +59.2% |
| 3 months ago | $9.03 | $1,050.94 | +5.1% |
| 6 months ago | $10.73 | $884.44 | -11.6% |
| 1 year ago | $4.69 | $2,023.45 | +102.3% |
| All time (5.0y) ago | $21.52 | $440.99 | -55.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PSNL forecast.
Our base-case forecast reaches $19.00 around 2030.
Implied market cap at $19.00: $1.99B
The multi-year forecast lays out a clear upside trajectory. In 2026 the min price is $5.04, the avg price is $9.49, and the max price is $14.74, with ROI of 0% and neutral sentiment. By 2030 the avg price rises to $21.42 with a max of $35.52 and a min of $13.97, and ROI of 125.7% with bullish sentiment.
The forecast continues higher, with 2040 showing an avg of $61.20 (max $125.35, min $29.47) and ROI of 544.9%, and 2050 projecting an avg of $151.56 (max $348.59, min $68.20) with ROI of 1497.1% and bullish sentiment. These figures imply substantial long-run upside while recognizing that real outcomes may differ from forecasts.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg price of $21.42, with a max of $35.52 and a min of $13.97, and a predicted ROI of 125.7% with bullish sentiment.
Yes. The 2050 forecast lists an avg price of $151.56, a max of $348.59, and a min of $68.20, with a ROI of 1497.1% and bullish sentiment.
The 2035 max price is $61.46 and the 2032 max price is $52.11, indicating the possibility of reaching around or above $60 in the forecast window.
Over the past 30 days the range has been $7.03 to $12.82, with current price $9.49 and RSI14 at 80, indicating bullish momentum near a resistance level of $9.49 and a support level of $5.04.
Long-term milestones include 2040 with an avg price of $61.20 and a max of $125.35 (ROI 544.9%), and 2050 with an avg price of $151.56 and a max of $348.59 (ROI 1497.1%), both with bullish sentiment.
Personalis, Inc. Community Discussion
0Share your Personalis, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.